Penbrook Management LLC Sells 600 Shares of Novo Nordisk A/S (NYSE:NVO)

Penbrook Management LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 312,600 shares of the company’s stock after selling 600 shares during the period. Novo Nordisk A/S accounts for about 24.9% of Penbrook Management LLC’s portfolio, making the stock its largest position. Penbrook Management LLC’s holdings in Novo Nordisk A/S were worth $40,138,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of NVO. Pacific Center for Financial Services raised its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. First PREMIER Bank acquired a new position in Novo Nordisk A/S during the first quarter worth $25,000. CNB Bank acquired a new position in Novo Nordisk A/S during the fourth quarter worth $26,000. West Paces Advisors Inc. raised its holdings in Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after buying an additional 150 shares during the last quarter. Finally, Valued Wealth Advisors LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $28,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday. Argus increased their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price for the company. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Stock Performance

NVO traded down $2.44 during trading on Tuesday, hitting $142.98. 5,901,097 shares of the company traded hands, compared to its average volume of 4,452,005. The firm has a market cap of $641.63 billion, a P/E ratio of 49.24, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. The stock’s fifty day moving average is $135.40 and its 200 day moving average is $124.04. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.06. The company had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.